Notable Recent Publications

These are some recent publications which give a flavour of the research from the Barclay lab. For a complete list of publications, please see below.


Species difference in ANP32A underlies influenza A virus polymerase host restriction. Nature (2016).
Jason S. Long, Efstathios S. Giotis, Olivier Moncorgé, Rebecca Frise, Bhakti Mistry, Joe James, Mireille Morisson, Munir Iqbal, Alain Vignal, Michael A. Skinner & Wendy S. Barclay

This paper identified a key factor that explained why the polymerases from avian influenza viruses are restricted in humans.  For more, please see the associated New and Views.

See our latest ANP32 papers here: eLIFE, Journal of Virology, Journal of Virology.


The mechanism of resistance to favipiravir in influenza. PNAS (2018).
Daniel H. GoldhillAartjan J. W. te VelthuisRobert A. FletcherPinky LangatMaria ZambonAngie Lackenby & Wendy S. Barclay

This paper showed how influenza could evolve resistance to favipiravir, an antiviral that may be used to treat influenza. The residue that mutated to give resistance was highly conserved suggesting that the mechanism of resistance may be applicable to other RNA viruses.


Internal genes of a highly pathogenic H5N1 influenza virus determine high viral replication in myeloid cells and severe outcome of infection in mice. Plos Path. (2018).
Hui Li*, Konrad C. Bradley*, Jason S. Long, Rebecca Frise, Jonathan W. Ashcroft, Lorian C. Hartgroves, Holly Shelton, Spyridon Makris, Cecilia Johansson, Bin Cao & Wendy S. Barclay

Why do avian influenza viruses like H5N1 cause such severe disease in humans? This paper demonstrated that H5N1 viruses replicate better than human viruses in myeloid cells from mice leading to a cytokine storm and more severe disease.


Citation

BibTex format

@article{Everitt:2012:10.1038/nature10921,
author = {Everitt, AR and Clare, S and Pertel, T and John, SP and Wash, RS and Smith, SE and Chin, CR and Feeley, EM and Sims, JS and Adams, DJ and Wise, HM and Kane, L and Goulding, D and Digard, P and Anttila, V and Baillie, JK and Walsh, TS and Hume, DA and Palotie, A and Xue, Y and Colonna, V and Tyler-Smith, C and Dunning, J and Gordon, SB and GenISIS, Investigators and MOSAIC, Investigators and Smyth, RL and Openshaw, PJ and Dougan, G and Brass, AL and Kellam, P},
doi = {10.1038/nature10921},
journal = {Nature},
pages = {519--523},
title = {IFITM3 restricts the morbidity and mortality associated with influenza.},
url = {http://dx.doi.org/10.1038/nature10921},
volume = {484},
year = {2012}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - The 2009 H1N1 influenza pandemic showed the speed with which a novel respiratory virus can spread and the ability of a generally mild infection to induce severe morbidity and mortality in a subset of the population. Recent in vitro studies show that the interferon-inducible transmembrane (IFITM) protein family members potently restrict the replication of multiple pathogenic viruses1, 2, 3, 4, 5, 6, 7. Both the magnitude and breadth of the IFITM proteins’ in vitro effects suggest that they are critical for intrinsic resistance to such viruses, including influenza viruses. Using a knockout mouse model8, we now test this hypothesis directly and find that IFITM3 is essential for defending the host against influenza A virus in vivo. Mice lacking Ifitm3 display fulminant viral pneumonia when challenged with a normally low-pathogenicity influenza virus, mirroring the destruction inflicted by the highly pathogenic 1918 ‘Spanish’ influenza9, 10. Similar increased viral replication is seen in vitro, with protection rescued by the re-introduction of Ifitm3. To test the role of IFITM3 in human influenza virus infection, we assessed the IFITM3 alleles of individuals hospitalized with seasonal or pandemic influenza H1N1/09 viruses. We find that a statistically significant number of hospitalized subjects show enrichment for a minor IFITM3 allele (SNP rs12252-C) that alters a splice acceptor site, and functional assays show the minor CC genotype IFITM3 has reduced influenza virus restriction in vitro. Together these data reveal that the action of a single intrinsic immune effector, IFITM3, profoundly alters the course of influenza virus infection in mouse and humans.
AU - Everitt,AR
AU - Clare,S
AU - Pertel,T
AU - John,SP
AU - Wash,RS
AU - Smith,SE
AU - Chin,CR
AU - Feeley,EM
AU - Sims,JS
AU - Adams,DJ
AU - Wise,HM
AU - Kane,L
AU - Goulding,D
AU - Digard,P
AU - Anttila,V
AU - Baillie,JK
AU - Walsh,TS
AU - Hume,DA
AU - Palotie,A
AU - Xue,Y
AU - Colonna,V
AU - Tyler-Smith,C
AU - Dunning,J
AU - Gordon,SB
AU - GenISIS,Investigators
AU - MOSAIC,Investigators
AU - Smyth,RL
AU - Openshaw,PJ
AU - Dougan,G
AU - Brass,AL
AU - Kellam,P
DO - 10.1038/nature10921
EP - 523
PY - 2012///
SP - 519
TI - IFITM3 restricts the morbidity and mortality associated with influenza.
T2 - Nature
UR - http://dx.doi.org/10.1038/nature10921
UR - http://www3.imperial.ac.uk/newsandeventspggrp/imperialcollege/newssummary/news_26-3-2012-10-26-46
UR - http://hdl.handle.net/10044/1/19031
VL - 484
ER -

Contact us


For any enquiries related to this group, please contact:

Professor Wendy Barclay
Chair in Influenza Virology 
+44 (020) 7594 5035
w.barclay@imperial.ac.uk